文献速递心律失常心力衰竭与心肌病

起搏器植入后心力衰竭发生率:丹麦全国注册随访研究

Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study.
PubMed 文献 · Eur Heart J · 2019-01-01

结果显示起搏器患者2年内心力衰竭累积发生率为10.6%,风险主要在术后6个月内显著升高,尤其前30天风险最高,既往心肌梗死和慢性肾病者风险更高。

要点

  • 右心室起搏电极起搏器植入后6个月内心力衰竭风险显著升高,前30天风险最高。
  • 起搏器患者2年内包括致死性心力衰竭的累积发生率为10.6%。
  • 男性、慢性肾病和既往心肌梗死与起搏器术后心力衰竭风险增加相关。

核心结论

  • 植入右心室起搏电极的起搏器与心力衰竭风险强烈相关,尤其在术后前6个月。
  • 既往有心肌梗死和慢性肾病的患者心力衰竭风险显著增加。

研究设计与样本

  • 主要结局为起搏器植入后2年内包括致死性心力衰竭的累积发生率,全因死亡和心肌梗死作为竞争风险。
  • 因违反比例风险假定,随访分为<30天、30—180天和>180天至2年三个时间段。

主要发现

  • 起搏器患者中包括致死性心力衰竭的累积发生率为2937例(10.6%)。
  • 术后<30天心力衰竭风险HR为5.98(95%CI 5.19—6.90)。
  • 术后30—180天心力衰竭风险HR为1.84(95%CI 1.71—1.98)。
  • 术后>180天至2年心力衰竭风险HR为1.11(95%CI 1.04—1.17)。
  • 起搏器患者中,男性HR 1.33(95%CI 1.24—1.43)、慢性肾病HR 1.64(95%CI 1.29—2.09)、既往心肌梗死HR 1.77(95%CI 1.50—2.09)与心力衰竭风险增加相关。

临床怎么用

  • 起搏器植入后应关注心力衰竭风险,尤其术后6个月内,对高风险患者加强随访。
  • 对男性、合并慢性肾病或既往心肌梗死的起搏器患者,应更积极评估心力衰竭症状和心功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The objective of the current study is to investigate the risk of heart failure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk. METHODS AND RESULTS: All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using Danish nationwide registries. An age- and gender-matched control cohort (matched 1:5, n = 138 520) without PM and HF was identified to compare the risk. Outcome was the cumulative incidence of HF including fatal HF within the first 2 years of PM implantation, with all-cause mortality and myocardial infarction (MI) as competing risks. Due to violation of proportional hazards, the follow-up period was divided into three time-intervals: <30 days, 30-180 days, and >180 days-2 years. The cumulative incidence of HF including fatal HF was observed in 2937 (10.6%) PM patients. Risks for the three time-intervals were <30 days [hazard ratio (HR) 5.98, 95% CI 5.19-6.90], 30-180 days (HR 1.84, 95% CI 1.71-1.98), and >180 days (HR 1.11, 95% CI 1.04-1.17). Among patients with a PM device, factors associated with increased risk of HF were male sex (HR 1.33, 95% CI 1.24-1.43), presence of chronic kidney disease (CKD) (HR 1.64, 95% CI 1.29-2.09), and prior MI (1.77, 95% 1.50-2.09). CONCLUSIONS: Pacemaker with an RVP lead is strongly associated with risk of HF specifically within the first 6 months. Patients with antecedent history of MI and CKD had substantially increased risk.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Tayal B, Fruelund P, Sogaard P, et al. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study. Eur Heart J. 2019. PMID: 31504437. doi:10.1093/eurheartj/ehz584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。